摘要
目的:探讨临床上丹红注射液联合依达拉奉治疗急性脑梗死的有效性与安全性。方法:随机将126例急性脑梗死患者分为对照组和实验组各63例,两组均使用每日1次吸氧、抗凝、保护脑细胞等一般康复措施作为基础治疗,此外对照组给予依达拉奉静脉滴注,实验组给予依达拉奉和丹红注射液联合静脉滴注,10 d为1个疗程。3个疗程后对比两组治疗前后神经功能损害程度和日常生活能力改善情况。结果:实验组比对照组的神经功能缺损程度NIHSS评分明显降低,而日常生活能力ADL评分明显提高,且均具有统计学显著性(P<0.05)。总体有效率上,实验组92.06%明显优于对照组的69.84%。结论:丹红注射液联合依达拉奉治疗急性脑梗死疗效确切,比使用依达拉奉单药治疗效果更好,并且安全性好,值得在临床上进行推广。
Objective： To investigate the clinical application value of Danhong injection combined with edaravone in treatment of acute cerebral infarction.Method： One hundred and twenty-six cases patients with acute cerebral infarction were selected,63 of them in control group and experimental group each.Both group received general rehabilitation measures such as daily oxygen uptake,anticoagulation treatment,brain cells protection.Additionally,control group got edaravone intravenously only and experimental group received Danhong injection combined with edaravone.10 days was taken as a course.After three courses,degree of neurological impairment and improvement of daily living activities was evaluated and compared with before.Result： The NIHSS score of neurological deficit was significant lower in the experimental group than the control group,and the activities of daily living（ADL） score of daily living ability was significant higher in the experimental group than the control group.Both the difference were statistically significant.Overall efficiency of the experimental group was 91.67%,significantly better than the control group＇s 70.21%.Conclusion： It is a safe and effective method to use Danhong injection combined with edaravone in treatment of acute cerebral infarction.The combination therapy is better than edaravone monotherapy and it＇s worthy of promotion in clinical practice.
出处
《中国实验方剂学杂志》
CAS
北大核心
2013年第18期315-317,共3页
Chinese Journal of Experimental Traditional Medical Formulae
基金
瑞安市科技计划项目(201204008)
关键词
丹红注射液
依达拉奉
联合治疗
急性脑梗死
Danhong injection
edaravone
combination therapy
acute cerebral infarction
